Author/Authors :
Ahmadzadehfar, Hojjat Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany , Aryana, Kamran Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran , Pirayesh, Elahe Department of Nuclear Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran , Farzanehfar, Saeed Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran , Assadi, Majid The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , Fallahi, Babak Research Centre for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran , Shafiei, Babak Department of Nuclear Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ayati, Narjess Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran , Amoui, Mahasti Department of Nuclear Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein, which is anchored in the cell membrane of
prostate epithelial cells. It is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer.
Although, 177Lu-PSMA has been recently introduced for radionuclide therapy of metastatic castration-resistant prostate cancer
(mCRPC) with continuously increasing interest and use worldwide. This guideline is intended to assist nuclear medicine
physicians in evaluating and managing patients with mRCPC for whom radioligand therapy (RLT) using 177Lu-PSMA is a
promising treatment option. In addition, more information could be provided by subsequent investigative studies in the field
of RLT.
